Brändli H H, Hefti M L, Blum A L
Schweiz Med Wochenschr. 1977 Dec 3;107(48):1770-3.
A 2-year prospective study with chenodeoxycholic acid (CDCA) (750 mg per day) was performed in 34 asymptomatic patients with radiolucent gallstones. 17 patients dropped out before completion of the trial. In 5 cases (29%) the stones dissolved and in 5 additional cases they decreased in size, while in 2 cases (13%) they increased in size during treatment. Favorable criteria for dissolution were round stones without edges and fissures on radiological appearance and a stone diameter of less than 1 cm. In 3 cases drug-induced nausea or diarrhea were so pronounced that treatment could not be continued. CDCA treatment also caused a significant rise in SGPT for at least one year. Thus, CDCA is at best moderately effective in a highly selective group of patients with gallstones.
对34例无症状的透X线胆结石患者进行了一项为期2年的鹅去氧胆酸(CDCA)(每日750毫克)前瞻性研究。17例患者在试验完成前退出。5例(29%)结石溶解,另有5例结石尺寸减小,而2例(13%)在治疗期间结石尺寸增大。结石溶解的有利标准为放射学表现上无边缘和裂隙的圆形结石且结石直径小于1厘米。3例患者药物引起的恶心或腹泻非常严重,以至于无法继续治疗。CDCA治疗还导致谷丙转氨酶(SGPT)显著升高至少一年。因此,CDCA对高度选择性的胆结石患者群体充其量只有中等疗效。